Skip to content
Screener

Integra LifeSciences IART Cash & Equivalents

Cash & Equivalents at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$708M-11.3%
Stryker logo
StrykerSYK
$3.39B+42.8%
Sanara MedTech Inc. logo
Sanara MedTech Inc.SMTI
$13.59M-34.3%
Axogen logo
AxogenAXGN
$96.57M+271%
Globus Medical logo
Globus MedicalGMED
$507.75M+121%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
$36.52M+195%

Other financials

Income statement

See full
Revenue$418.8M+0.8%
Gross profit$219.7M+5.0%
Operating income$19.3M+104%
Net income$4.5M+101%
EPS (diluted)$0.06+101%

Balance sheet

See full
Total debt$2.0B+3.2%
Total equity$1.0B+0.5%
Total assets$3.6B-2.8%

Cash flow

See full
Operating cash flow$22.8M+156%
CapEx$12.3M-38.9%
Free cash flow$10.5M+193%

Valuation

See full
Market cap$1.33B+38.0%
Enterprise value$3.08B+16.2%
P/S0.8×+0.2×

Profitability

See full
Gross margin52.5%-0.1pp
Operating margin2.6%+1.3pp
Net margin-0.4%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-0.7%
Debt / equity1.9×+0.1×
Current ratio3.6×+2.4×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000917520-26-000058
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Payments for contingent considerations(6,842)(16,451)
Proceeds from exercised stock options and employee stock purchase plan760957
Cash taxes paid in net equity settlement(1,589)(2,361)
Net cash provided by financing activities7,47914,238
Effect of exchange rate changes on cash and cash equivalents(2,586)17,207
Net decrease in cash and cash equivalents(20,633)(28,461)
Cash and cash equivalents at beginning of period235,048246,375
Cash and cash equivalents at end of period$214,415$217,914

Item 1. Financial Statements

FAQ

What is Integra LifeSciences's cash & equivalents?
Integra LifeSciences (IART) reported cash & equivalents of $214.42M in Q2 2026.
How has Integra LifeSciences's cash & equivalents changed year-over-year?
Integra LifeSciences's cash & equivalents decreased by 1.6% year-over-year, from $217.91M to $214.42M.
What is the long-term trend for Integra LifeSciences's cash & equivalents?
Over 5 years (2020 to 2025), Integra LifeSciences's cash & equivalents has grown at a -12.9% compound annual growth rate (CAGR), from $470.17M to $235.05M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Integra LifeSciences's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude